<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204279</url>
  </required_header>
  <id_info>
    <org_study_id>NEPA-15-31</org_study_id>
    <nct_id>NCT03204279</nct_id>
  </id_info>
  <brief_title>PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting</brief_title>
  <acronym>CINV</acronym>
  <official_title>A Multicenter Multinational Randomized Double Blind PK/PD Dose-finding Study of Oral Netupitant Given With Oral Palonosetron in Pediatric Cancer Patients for Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) dose-finding study of&#xD;
      oral netupitant administered concomitantly with oral palonosetron in pediatric cancer&#xD;
      patients for the prevention of nausea and vomiting associated with emetogenic chemotherapy.&#xD;
      Two different netupitant dosages will be tested in patients aged from 3 months to &lt; 18 years:&#xD;
      1.33 mg/kg up to a maximum of 100 mg, and 4 mg/kg up to a maximum of 300 mg. All netupitant&#xD;
      doses in all age classes will be concomitantly administered with palonosetron 20 μg/kg (up to&#xD;
      a maximum dose of 1.5 mg) which is the IV palonosetron dose approved by USA FDA for the&#xD;
      pediatric population. The primary objective is to investigate the PK/PD relationship between&#xD;
      netupitant exposure (AUC, Cmax) and antiemetic efficacy (CR in delayed phase) after a single&#xD;
      oral netupitant administration, concomitantly with oral palonosetron in pediatric cancer&#xD;
      patients receiving Moderately Emetogenic Chemotherapy (MEC) or Highly Emetogenic Chemotherapy&#xD;
      (HEC) cycles. Efficacy parameter to be used in the correlation is the proportion of patients&#xD;
      with Complete Response (CR i.e., no emetic episodes and no rescue medication) during (&gt;&#xD;
      24-120 h after the start of chemotherapy on Day 1).&#xD;
&#xD;
      The secondary objectives are to assess the safety and tolerability after single oral&#xD;
      administration of netupitant given concomitantly with a single oral administration of&#xD;
      palonosetron; to evaluate the pharmacokinetic (AUC, Cmax, tmax and t1/2) of oral palonosetron&#xD;
      at the fixed dose of 20 μg/kg in pediatric patients with the concomitant administration of&#xD;
      netupitant. A total of 92 pediatric cancer patients receiving either HEC or MEC will be&#xD;
      enrolled in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant</measure>
    <time_frame>within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h.</time_frame>
    <description>Mean values of area under the plasma Concentration versus time curve from time zero to infinity (AUC0-inf) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. AUC estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Netupitant</measure>
    <time_frame>within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h</time_frame>
    <description>Mean values of maximum plasma concentration (Cmax) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. Cmax estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exposure - Response Analysis for Netupitant</measure>
    <time_frame>&gt; 24-120 hours after the start of chemotherapy on Day 1</time_frame>
    <description>Exposure - Response analysis for netupitant performed by assessing the relationships between exposure parameters AUC0-inf and Cmax with the primary efficacy endpoint, i.e., the CR in the delayed phase.&#xD;
Graphical exposure-response analysis for netupitant performed by assessing the relationship between individual exposure parameters (AUC0-inf) and Cmax) with the primary efficacy endpoint, i.e the CR in the delayed phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Pediatric Patients With Complete Response During the Delayed Phase</measure>
    <time_frame>&gt; 24-120 hours after the start of chemotherapy on Day 1</time_frame>
    <description>Percentage of Pediatric Patients with complete response (CR, i.e., no emetic episodes and no rescue medication) during the delayed phase (&gt; 24 to 120 h after the start of chemotherapy on Day 1) after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting (CINV)</condition>
  <arm_group>
    <arm_group_label>Netupitant 1.33 mg/kg plus Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Netupitant 4 mg/kg plus Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netupitant</intervention_name>
    <description>Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg</description>
    <arm_group_label>Netupitant 1.33 mg/kg plus Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
    <arm_group_label>Netupitant 1.33 mg/kg plus Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netupitant</intervention_name>
    <description>Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg</description>
    <arm_group_label>Netupitant 4 mg/kg plus Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
    <arm_group_label>Netupitant 4 mg/kg plus Palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent by parent(s)/legal guardians of the pediatric patient&#xD;
             in compliance with the local laws and regulations. In addition signed children's&#xD;
             assent form according to local requirements.&#xD;
&#xD;
          2. Male or female in- or out-patient from birth to &lt; 18 years at the time of&#xD;
             randomization.&#xD;
&#xD;
          3. Patient weight at least 3.3 kg.&#xD;
&#xD;
          4. Naïve or non-naïve patient with histologically, and/or cytologically (or imaging in&#xD;
             the case of brain tumors) confirmed malignant disease.&#xD;
&#xD;
          5. Scheduled and eligible to receive at least one moderately or highly emetogenic&#xD;
             chemotherapeutic agent on Day 1 only or for multiple days.&#xD;
&#xD;
          6. For patient aged ≥ 10 years: Eastern Cooperative Oncology Group Performance Status&#xD;
             (ECOG PS) ≤ 2.&#xD;
&#xD;
          7. For patient aged 2 years with known mild to moderate hepatic impairment: in the&#xD;
             Investigator's opinion the impairment does not jeopardize patient's safety during the&#xD;
             study.&#xD;
&#xD;
          8. For patient aged 2 years with known mild to moderate renal impairment: in the&#xD;
             Investigator's opinion the impairment should not jeopardize patient's safety during&#xD;
             the study.&#xD;
&#xD;
          9. For patient with known history or predisposition to cardiac abnormalities: in the&#xD;
             Investigator's opinion the history/predisposition should not jeopardize patient's&#xD;
             safety during the study.&#xD;
&#xD;
         10. If the patient is female, she shall: a) not have attained menarche yet or b) have&#xD;
             attained menarche and have a negative pregnancy test at the screening visit and at Day&#xD;
             1.&#xD;
&#xD;
         11. Male or female fertile patient using reliable contraceptive measures (such measures,&#xD;
             for patient and sexual partner, include: implants, injectables, combined oral&#xD;
             contraceptives, intrauterine devices, vasectomized/sterilized partner, use of a&#xD;
             double-barrier method or sexual abstinence). The patient and his/her parent(s)/legal&#xD;
             guardians must be counseled on the importance of avoiding pregnancy before or during&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient and/or parents/caregivers are expected by the Investigator to be&#xD;
             non-compliant with the study procedures.&#xD;
&#xD;
          2. Patient has received or is scheduled to receive total body irradiation, total nodal&#xD;
             irradiation, upper abdomen radiotherapy, half or upper body irradiation, radiotherapy&#xD;
             of the cranium, craniospinal regions, head and neck, lower thorax region or the pelvis&#xD;
             within 1 week prior to study entry (Day 1) or within 120 h after start of chemotherapy&#xD;
             administration on Day 1.&#xD;
&#xD;
          3. Known history of allergy to any component or other contraindications to any&#xD;
             Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.&#xD;
&#xD;
          4. Active infection.&#xD;
&#xD;
          5. Uncontrolled medical condition (e.g., uncontrolled insulin dependent diabetes&#xD;
             mellitus).&#xD;
&#xD;
          6. Patient suffering from ongoing vomiting from any organic etiology (including patients&#xD;
             with history of gastric outlet obstruction or intestinal obstruction due to adhesions&#xD;
             or volvulus, patients with a symptomatic central nervous system(CNS) tumor causing&#xD;
             nausea and/or vomiting) or patient with hydrocephalus.&#xD;
&#xD;
          7. Patient who experienced any vomiting, retching, or nausea within 24 h prior to the&#xD;
             administration of the study drug&#xD;
&#xD;
          8. Patient who received any drug with potential anti-emetic effect within 24 h prior to&#xD;
             the start of reference chemotherapy, including but not limited to:&#xD;
&#xD;
             NK1- receptor antagonists (e.g., aprepitant or any other new drug of this class);&#xD;
             5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron,&#xD;
             ramosetron); Benzamides (e.g., metoclopramide, alizapride); Phenothiazines (e.g.,&#xD;
             prochlorperazine, promethazine, perphenazine, fluphenazine, chlorpromazine,&#xD;
             thiethylperazine); Benzodiazepines initiated 48 h prior to study drug administration&#xD;
             or expected to be received within 120 h following initiation of chemotherapy, except&#xD;
             for single doses of midazolam, temazepam or triazolam; Butyrophenones (e.g.,&#xD;
             droperidol, haloperidol); Anticholinergics (e.g., scopolamine, with the exception of&#xD;
             inhaled anticholinergics for respiratory disorders e.g., ipratropium bromide);&#xD;
             Antihistamines (e.g., diphenhydramine, cyclizine, hydroxyzine, chlorpheniramine,&#xD;
             dimenhydrinate, meclizine); Domperidone; Mirtazapine; Olanzapine; Prescribed&#xD;
             cannabinoids (e.g., tetrahydrocannabinol, nabilone); Over the Counter (OTC)&#xD;
             antiemetics, OTC cold or OTC allergy medications; Herbal preparations containing&#xD;
             ephedra or ginger.&#xD;
&#xD;
          9. Patient who received palonosetron within 1 week prior to administration of study drug.&#xD;
&#xD;
         10. Patient who has been started on systemic corticosteroid therapy within 72 h prior to&#xD;
             study drug administration or is planned to receive a corticosteroid as part of the&#xD;
             chemotherapy regimen&#xD;
&#xD;
         11. Patient aged &lt; 6 years who received any investigational drug (defined as a medication&#xD;
             with no marketing authorization granted for any age class and any indication) within&#xD;
             90 days prior to Day 1, or patient aged 6 years who received any investigational drug&#xD;
             within 30 days prior to Day 1 or is expected to receive investigational drugs prior to&#xD;
             study completion.&#xD;
&#xD;
         12. Intake of alcohol, food or beverages (e.g., grapefruit, cranberry, pomegranate and&#xD;
             aloe vera juices, German chamomile) known to interfere with either CYP3A4 or CYP2D6&#xD;
             metabolic enzymes within 1 week prior to Day 1 and during the overall study period.&#xD;
&#xD;
         13. Use of any drugs or substances known to be strong or moderate inhibitors of CYP3A4 and&#xD;
             CYP2D6 enzymes within 1 week prior to Day 1 or planned to be used during the overall&#xD;
             study period.&#xD;
&#xD;
         14. Use of any drugs or substances known to be CYP3A4 substrates with narrow therapeutic&#xD;
             range within 1 week prior to Day 1, or planned to be used during the overall study&#xD;
             period.&#xD;
&#xD;
         15. Use of any drugs or substances known to be inducers of CYP3A4 enzymes within 4 weeks&#xD;
             prior to Day 1 or planned to be used during the overall study period.&#xD;
&#xD;
         16. Lactating female patient.&#xD;
&#xD;
         17. Patient with clinically relevant abnormal laboratory values that in the Investigator's&#xD;
             opinion jeopardize the patient's safety during the study.&#xD;
&#xD;
         18. Patient aged &lt; 2 years with known hepatic impairment (any grade), or patient aged 2&#xD;
             years with known severe hepatic impairment.&#xD;
&#xD;
         19. Patient aged &lt; 2 years with known renal impairment (any grade), or patient aged 2&#xD;
             years with known severe renal impairment.&#xD;
&#xD;
         20. Enrolment in a previous study with netupitant (either alone or in combination with&#xD;
             palonosetron).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nemours/A.I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center - Cancer Medicine and Blood Disorders - Scarborough</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Children's Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Territorial Clinical Hospital</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dmitry Rogachev National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #31</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First I.P. Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Children's Cinical Hospital #1</name>
      <address>
        <city>Voronezh</city>
        <zip>394024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital #1</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital, Center for Pediatrics, Department of Hematology and Oncology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis, Clinic of Pediatric Internal Diseases</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Regional Children's Clinical Hospital</name>
      <address>
        <city>Dnipro</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cancer, Research Department of Pediatric Oncology</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Ukrainian Specialized Children's Medical Center, Department of Pediatric Surgery</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>September 16, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03204279/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
        <group group_id="P2">
          <title>Netupitant 4 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Male and female pediatric cancer patients from birth up to &lt;18 years, who were scheduled to receive HEC or MEC to be administered as single-day chemotherapy on Day 1 only or for multiple days. All participants who received study drug. In netupitant 4 mg/kg arm 1 patient was withdrew from the study after randomization of study drug and was not treated with the study drug (the overall number of participants started in netupitant 4 mg/kg arm was 33 and 32 patients completed the study).</population>
      <group_list>
        <group group_id="B1">
          <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
        <group group_id="B2">
          <title>Netupitant 4 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="6.29"/>
                    <measurement group_id="B2" value="5.6" spread="5.46"/>
                    <measurement group_id="B3" value="6.1" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>3 to &lt;6 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 to &lt;12 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 to &lt;2 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 to &lt;5 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 to &lt;12 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12 to &lt;18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 to &lt;3 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant</title>
        <description>Mean values of area under the plasma Concentration versus time curve from time zero to infinity (AUC0-inf) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. AUC estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles.</description>
        <time_frame>within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h.</time_frame>
        <population>Pediatric patients divided in seven age groups; in netupitant 4 mg/kg arm 1 patient was withdrew from the study after randomization of study drug and was not treated; 1 patient was treated with study drug but did not receive the entire planned dose and was not included in this analysis and one patient received the entire planned dose, but did not have any measurable concentration of netupitant and/or palonosetron.</population>
        <group_list>
          <group group_id="O1">
            <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Netupitant 4 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant</title>
          <description>Mean values of area under the plasma Concentration versus time curve from time zero to infinity (AUC0-inf) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. AUC estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles.</description>
          <population>Pediatric patients divided in seven age groups; in netupitant 4 mg/kg arm 1 patient was withdrew from the study after randomization of study drug and was not treated; 1 patient was treated with study drug but did not receive the entire planned dose and was not included in this analysis and one patient received the entire planned dose, but did not have any measurable concentration of netupitant and/or palonosetron.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>patients 1 month to &lt;3 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 3 month to &lt;6 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3849" spread="91.3"/>
                    <measurement group_id="O2" value="17340" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 6 month to &lt;1 year of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7637" spread="113"/>
                    <measurement group_id="O2" value="8617" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 1 year to &lt;2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2276" spread="29.8"/>
                    <measurement group_id="O2" value="9886" spread="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 2 years to &lt;5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3135" spread="44.0"/>
                    <measurement group_id="O2" value="14404" spread="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 5 years to &lt;12 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2676" spread="35.0"/>
                    <measurement group_id="O2" value="10154" spread="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients 12 years to &lt;18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3107" spread="54.9"/>
                    <measurement group_id="O2" value="12266" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Netupitant</title>
        <description>Mean values of maximum plasma concentration (Cmax) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. Cmax estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles</description>
        <time_frame>within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h</time_frame>
        <population>Pediatric patients divided in seven age groups; in netupitant 4 mg/kg arm 1 patient was withdrew from the study after randomization of study drug and was not treated; 1 patient was treated with study drug but did not receive the entire planned dose and was not included in this analysis and one patient received the entire planned dose, but did not have any measurable concentration of netupitant and/or palonosetron.</population>
        <group_list>
          <group group_id="O1">
            <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Netupitant 4 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Netupitant</title>
          <description>Mean values of maximum plasma concentration (Cmax) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. Cmax estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles</description>
          <population>Pediatric patients divided in seven age groups; in netupitant 4 mg/kg arm 1 patient was withdrew from the study after randomization of study drug and was not treated; 1 patient was treated with study drug but did not receive the entire planned dose and was not included in this analysis and one patient received the entire planned dose, but did not have any measurable concentration of netupitant and/or palonosetron.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month to &lt;3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="NA">For only one measurement CV is not available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months to &lt;6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="27.1"/>
                    <measurement group_id="O2" value="233" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months to &lt;12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" spread="71.7"/>
                    <measurement group_id="O2" value="255" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year to &lt;2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" spread="19.3"/>
                    <measurement group_id="O2" value="275" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="32.3"/>
                    <measurement group_id="O2" value="266" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 years to &lt;12 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="32.1"/>
                    <measurement group_id="O2" value="213" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to &lt;18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" spread="27.3"/>
                    <measurement group_id="O2" value="274" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exposure - Response Analysis for Netupitant</title>
        <description>Exposure - Response analysis for netupitant performed by assessing the relationships between exposure parameters AUC0-inf and Cmax with the primary efficacy endpoint, i.e., the CR in the delayed phase.&#xD;
Graphical exposure-response analysis for netupitant performed by assessing the relationship between individual exposure parameters (AUC0-inf) and Cmax) with the primary efficacy endpoint, i.e the CR in the delayed phase.</description>
        <time_frame>&gt; 24-120 hours after the start of chemotherapy on Day 1</time_frame>
        <population>All pediatric patients with exposures parameters and CR data in the delayed phase</population>
        <group_list>
          <group group_id="O1">
            <title>Netupitant 1.33 mg/kg Plus Palonosetron or Netupitant 4 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Or Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure - Response Analysis for Netupitant</title>
          <description>Exposure - Response analysis for netupitant performed by assessing the relationships between exposure parameters AUC0-inf and Cmax with the primary efficacy endpoint, i.e., the CR in the delayed phase.&#xD;
Graphical exposure-response analysis for netupitant performed by assessing the relationship between individual exposure parameters (AUC0-inf) and Cmax) with the primary efficacy endpoint, i.e the CR in the delayed phase.</description>
          <population>All pediatric patients with exposures parameters and CR data in the delayed phase</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>number of participants with CR in delayed phase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>number of participants with no CR in delayed phase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The population consist of all patients having CR in the delayed phase and AUC0-inf and Cmax, there is no comparison between the two dose groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No comparison between the two dose groups is performed, thus no statistical test is applied. In the next section the goodness of fit of the loess function correlating exposure and response is reported.</non_inferiority_desc>
            <p_value>0.55</p_value>
            <p_value_desc>CR in the delayed phase vs AUC0-inf</p_value_desc>
            <method>loess (Local regression or polynomial)</method>
            <method_desc>The p-value represents the probability found if the correlation coefficient was zero (null hypothesis).</method_desc>
            <param_type>Pearson R</param_type>
            <param_value>0.076</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>R is the Pearson correlation is a coefficient statistic that measures linear correlation between two variables CR in the delayed phase vs AUC0-inf</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The population consist of all patients having CR in the delayed phase and AUC0-inf and Cmax, there is no comparison between the two dose groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No comparison between the two dose groups is performed, thus no statistical test is applied. In the next section the goodness of fit of the loess function correlating exposure and response is reported.</non_inferiority_desc>
            <p_value>0.75</p_value>
            <p_value_desc>CR in the delayed phase vs Cmax</p_value_desc>
            <method>loess (Local regression or polynomial)</method>
            <method_desc>The p-value represents the probability found if the correlation coefficient was zero (null hypothesis).</method_desc>
            <param_type>Pearson R</param_type>
            <param_value>- 0.041</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>R is the Pearson correlation is a coefficient statistic that measures linear correlation between two variables CR in the delayed phase vs Cmax</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Pediatric Patients With Complete Response During the Delayed Phase</title>
        <description>Percentage of Pediatric Patients with complete response (CR, i.e., no emetic episodes and no rescue medication) during the delayed phase (&gt; 24 to 120 h after the start of chemotherapy on Day 1) after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles.</description>
        <time_frame>&gt; 24-120 hours after the start of chemotherapy on Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Netupitant 4 mg/kg Plus Palonosetron</title>
            <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric Patients With Complete Response During the Delayed Phase</title>
          <description>Percentage of Pediatric Patients with complete response (CR, i.e., no emetic episodes and no rescue medication) during the delayed phase (&gt; 24 to 120 h after the start of chemotherapy on Day 1) after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug on Visit 2 (Day 1, inclusively) until Visit 5 (follow up, Day 14 [+3])</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Netupitant 1.33 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients &lt; 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
        <group group_id="E2">
          <title>Netupitant 4 mg/kg Plus Palonosetron</title>
          <description>Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients &lt; 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.&#xD;
Netupitant: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg&#xD;
Palonosetron: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edwin de Wit - Head of Clinical Development</name_or_title>
      <organization>Helsinn Healthcare SA</organization>
      <phone>+41 91 985 2121</phone>
      <email>info-HHC@helsinn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

